{
    "clinical_study": {
        "@rank": "99198", 
        "acronym": "IFM2013-04", 
        "arm_group": [
            {
                "arm_group_label": "VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD)", 
                "arm_group_type": "Active Comparator", 
                "description": "Arm A:\nInduction therapy 4 cycles of VTD (21 days) Thalidomide\u00ae 100 mg/day Per Os  Day1 to Day21 Velcade\u00ae 1.3 mg/m\u00b2/day Subcutaneous  Day1, 4, 8 and 11 Dexamethasone  40 mg/day Per Os Day 1 to 4 and Day 9 to 12\nSystematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and one week after the last dose of Thalidomide, stem cells have to be harvested"
            }, 
            {
                "arm_group_label": "VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD)", 
                "arm_group_type": "Active Comparator", 
                "description": "For arm B:\nInduction therapy : 4 cycles of VCD (21 days)\nCyclophosphamide  500 mg/m\u00b2/day, Per Os Day 1, 8, 15\nVelcade\u00ae and Dexamethasone identical treatment to Arm A\nSystematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and two weeks after the last dose of Cyclophosphamide, stem cells have to be harvested"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase III, multicenter, prospective with a clinical benefit, open-label and\n      randomized study to compare two different treatments : Velcade (Bortezomib) Thalidomide\n      Dexamethasone (VTD) versus Velcade (Bortezomib) Cyclophosphamide Dexamethasone (VCD) as an\n      Induction Treatment prior to Autologous Stem Cell Transplantation in patients with Newly\n      Diagnosed Multiple Myeloma.\n\n      Eligible patients will be randomized into 2 treatment arms. Each patient will receive 4\n      consecutive 21 day cycles of an induction treatment with either VTD or VCD."
        }, 
        "brief_title": "Efficacy Study Comparing VELCADE DEXAMETHASONE THALIDOMIDE Versus VELCADE CYCLOPHOSPHAMIDE DEXAMETHASONE as Induction Treatment in the Initial Management of Multiple Myeloma", 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "The patient population will consist of adult men and women who have a confirmed diagnosis of\n      Multiple Myeloma and who meet eligibility criteria. They will be recruited from among the\n      patients consulting in an investigating centre's haematology service for newly diagnosed,\n      symptomatic, untreated multiple myeloma.\n\n      in each treatment arm there will be :\n\n        1. Induction therapy : 4 cycles of VTD (21 days)or VCD\n\n        2. Systematic stem cell harvest after cycle 3"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients newly diagnosed with symptomatic Multiple Myeloma (MM) patient\n\n          1. -  18 \u2264 age < 66 years\n\n          2. -  Eastern Cooperative Oncology Group Performance Status of 0, 1 or 2\n\n          3. -  Patients must be eligible for Autologous Stem Cell Transplantation\n\n          4. -  Patients must have measurable disease by serum M-protein \u2265 10 g/L and/or urine\n             M-protein \u2265200mg/day\n\n          5. -  Female patients of child-bearing potential (FCBP):\n\n               -  Must agree to have medically supervised pregnancy tests prior to starting study\n                  and every 21 days, including 4 weeks after the end of study treatment. This\n                  applies even if the patient practices complete and continued sexual abstinence.\n\n               -  Must agree to use and be able to comply with effective contraception without\n                  interruption, 28 days prior to starting study drug, during the study therapy\n                  (including during periods of dose interruptions), and for 28 days after\n                  discontinuation of study therapy.\n\n          6. -  Male Patients:\n\n               -  Must agree to use a condom during sexual contact with a FCBP, throughout study\n                  drug therapy, during any dose interruption and for one week after\n                  discontinuation of study therapy\n\n               -  Must agree to not donate semen during study drug therapy and for one week after\n                  discontinuation of study therapy\n\n          7. -  All patients must:\n\n               -  Agree to abstain from donating blood while taking study drug therapy and for one\n                  week after discontinuation of study drug therapy\n\n               -  Agree not to share study medication with another person.\n\n          8. -  Patients must be capable of giving informed consent\n\n          9. -  Patients must be affiliated with French social security system\n\n        Exclusion Criteria:\n\n          1. - Asymptomatic Multiple myeloma\n\n          2. -  Non-secretory Multiple myeloma\n\n          3. -  Proven AL-amyloidosis\n\n          4. -  Age \u2265 66 years old\n\n          5. -  Prior or current systemic therapy for Multiple myeloma, including steroids (except\n             for emergency use of a 4-day block of dexamethasone between the screening phase and\n             randomization, maximum total dose allowed 160 mg)\n\n          6. -  Radiation therapy in the 2 weeks preceding randomization\n\n          7. -  National Cancer Institute grade \u2265 2 peripheral neuropathy\n\n          8. -  Haemoglobin < 8g/dL\n\n          9. -  Absolute neutrophil count < 1,000 cells / \u00b5L, platelet count < 50,000 cells / \u00b5L\n\n         10. - Creatinine level > 170 \u00b5mol/L or requiring dialysis.\n\n         11. - Bilirubin, transaminases or GamaGT > 3 UNL (upper normal limit)\n\n         12. - Positive HIV serology, evidence of active Hepatitis B and C infection\n\n         13. -  Severe active infection\n\n         14. -  Inability to comply with an anti-thrombotic treatment regimen\n\n         15. -  A personal medical history of severe psychiatric disease\n\n         16. -  Uncontrolled diabetes contraindicating the use of high-dose dexamethasone\n\n         17. -  Non-controlled or severe cardiovascular disease (including a myocardial infarction\n             in the 6 months prior to recruitment)\n\n         18. -  Left Ventricular Ejection Fraction < 50%\n\n         19. -  Respiratory compromise, defined as ventilation tests with DLCO <50 % N\n\n         20. -  A personal medical history of cancer (except for basocellular skin cancer or in\n             situ cervical cancer)\n\n         21. -  Use of any investigational drug in the 30 days preceding randomization\n\n         22. -  Pregnant or lactating women.\n\n         23. -   Adults under juridical protection\n\n         24. - Known or suspected hypersensitivity to any of the study therapies or excipients\n\n         25. -  Necessity of vaccination for yellow fever or with any other live vaccines"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "340", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01971658", 
            "org_study_id": "RC13_0284", 
            "secondary_id": "2013-003174-27"
        }, 
        "intervention": [
            {
                "arm_group_label": "VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD)", 
                "intervention_name": "Thalidomide\u00ae", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD)", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD)", 
                    "VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD)"
                ], 
                "intervention_name": "Velcade\u00ae", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD)", 
                    "VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD)"
                ], 
                "intervention_name": "Dexam\u00e9thasone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Thalidomide", 
                "Bortezomib", 
                "Dexamethasone", 
                "Dexamethasone acetate", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple myeloma", 
            "Newly Diagnosed"
        ], 
        "lastchanged_date": "October 23, 2013", 
        "location": {
            "contact": {
                "email": "philippe.moreau@chu-nantes.fr", 
                "last_name": "Philippe MOREAU", 
                "phone": "(0)2 40 08 32 57", 
                "phone_ext": "+33"
            }, 
            "facility": {
                "address": {
                    "city": "Nantes", 
                    "country": "France", 
                    "zip": "44093"
                }, 
                "name": "Nantes University Hospital"
            }, 
            "investigator": {
                "last_name": "Philippe MOREAU", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "A PHASE III STUDY OF VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD) VERSUS VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD) AS AN INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA.\"", 
        "overall_contact": {
            "email": "philippe.moreau@chu-nantes.fr", 
            "last_name": "Philippe MOREAU", 
            "phone": "(0)2 40 08 32 57", 
            "phone_ext": "+33"
        }, 
        "overall_official": {
            "affiliation": "Nantes University Hospital", 
            "last_name": "Philippe MOREAU", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "compare the Response assessment in both arms: the Very good partial remission rate  (according to the criteria IMWG) achieved with four courses of VTD with that achieved with four courses of VCD", 
            "measure": "Response assessment according to the criteria IMWG", 
            "safety_issue": "No", 
            "time_frame": "15-17 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01971658"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "compare the Response assessment in both arms: the following parameters after induction treatment with four courses of VTD  or four courses of VCD the Complete remission rate (according to the criteria IMWG)", 
                "measure": "Response assessment according to the criteria IMWG", 
                "safety_issue": "No", 
                "time_frame": "15 - 17 month"
            }, 
            {
                "description": "To evaluate the Safety of induction therapy", 
                "measure": "Number of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "15-17 month"
            }, 
            {
                "measure": "Number of collected stem cell", 
                "safety_issue": "No", 
                "time_frame": "17 month"
            }, 
            {
                "description": "To evaluate Overall and Progression-Free Survival", 
                "measure": "Number of death", 
                "safety_issue": "No", 
                "time_frame": "17 month"
            }, 
            {
                "description": "compare the Response assessment in both arms: Compare the following parameters after induction treatment with four courses of VTD or four courses of VCD the Partial remission rate (according to the criteria IMWG)", 
                "measure": "Response assessment according to the criteria IMWG", 
                "safety_issue": "Yes", 
                "time_frame": "15-17 month"
            }, 
            {
                "description": "Progression-Free Survival", 
                "measure": "Number of relapse according to the criteria IMWG", 
                "safety_issue": "No", 
                "time_frame": "17 month"
            }
        ], 
        "source": "Nantes University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nantes University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}